Bifunctional molecules for degradation of EGFR and methods of use
The present application provides bifunctional compounds of Formula (I): which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.
1. A compound of Formula:
or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein:
the Linker is a group that covalently binds to
and the Degron;
the Degron is
Y is a bond, (CH 2 ) 1-6 , (CH 2 ) 0-6 —O, (CH 2 ) 0-6 —C(O)NR 11 , (CH 2 ) 0-6 —NR 11 C(O), (CH 2 ) 0-6 —NH, or (CH 2 ) 0-6 —NR 12 ;
Z 1 is C(O) or C(R 13 ) 2 ;
R 11 is H or C 1 -C 6 alkyl;
R 12 is C 1 -C 6 alkyl or C(O)—C 1 -C 6 alkyl;
each R 13 is independently H or C 1 -C 3 alkyl;
each R 14 is independently C 1 -C 3 alkyl;
R 15 is H, deuterium, C 1 -C 3 alkyl, F, or Cl;
each R 16 is independently halogen, OH, C 1 -C 6 alkyl, or C 1 -C 6 alkoxy;
q is 0, 1, or 2; and
v is 0, 1, 2, or 3;
wherein the Degron is covalently bonded to the Linker via
A is phenyl or pyridinyl;
X is CH, C(C 1 -C 3 ) alkyl, or N;
R 1 is H or (C 1 -C 3 ) alkyl;
R 2 is (C 6 -C 10 ) aryl, or heteroaryl comprising one or two 5- to 7-membered rings and 1-4 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are each optionally substituted with one or more R 4 ;
each R 4 is independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, NO 2 , OH, CN, C(O)R 6 , C(O)OR 6 , C(O)NR 6 R 7 , NR 6 R 7 , (C 3 -C 7 ) cycloalkyl, heterocyclyl comprising a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S, (C 6 -C 10 ) aryl, and heteroaryl comprising one or two 5- to 7-membered rings and 1-4 heteroatoms selected from N, O, and S, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each optionally substituted with one or more R 5 ;
each R 5 is independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, NO 2 , OH, and CN;
each R 6 is independently H or (C 1 -C 3 ) alkyl;
each R 7 is independently H or (C 1 -C 3 ) alkyl;
R 3 is (C 1 -C 3 ) alkyl or
X 2 is N or CR 8 ;
R 8 is H, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, NO 2 , NH 2 , OH, or CN;
each R 9 is independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, NO 2 , NH 2 , OH, and CN;
n is 0 or 1; and
p is 0, 1, 2, or 3.
2. The compound of claim 1 , wherein the Linker is
wherein
p1 is an integer selected from 0 to 12;
p2 is an integer selected from 0 to 12;
p3 is an integer selected from 0 to 6;
each W is independently absent, CH 2 , O, S, NH, or NR 10 ;
Z is absent, CH 2 , O, NH, NR 10 , C(O)(CH 2 ) 0-3 , or NHC(O)(CH 2 ) 0-3 ;
each R 10 is independently H or C 1 -C 3 alkyl;
Q is absent or CH 2 C(O)NH; and
wherein the Linker is covalently bonded to the Degron via the
next to Q.
3. The compound of claim 2 , wherein X is N.
4. The compound of claim 2 , wherein A is phenyl.
5. The compound of claim 2 , wherein n is 0.
6. The compound of claim 2 , wherein R 3 is
7. The compound of claim 2 , wherein R 1 is H.
8. The compound of claim 2 , wherein R 2 is
9. The compound of claim 2 , wherein
10. The compound of claim 2 , wherein the Linker is selected from:
wherein TL is the connecting point to
11. The compound of claim 2 , wherein the Linker is selected from:
wherein TL is the connecting point to
12. The compound of claim 1 , wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. A method for the treatment of cancer mediated by epidermal growth factor receptor (EGFR), or a mutant thereof, comprising administering a therapeutically effective amount of a compound of claim 1 optionally in a pharmaceutically acceptable carrier to a human in need thereof.
15. The method of claim 14 , wherein the disease is lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, pancreas cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphomas, myelomas, or solid tumors.
16. The method of claim 14 , wherein the disease is lung cancer.
17. The method of claim 14 , wherein the disease is colon cancer.
18. The method of claim 14 , wherein the disease is breast cancer.